Last updated on January 2010

Myelofibrosis


Brief description of study

Myelofibrosis

Detailed Study Description

Study of the JAK Inhibitor INCB018424 tablet administered orally to subjects with primary myelofibrosis, post-polycythemia vera-myelofibrosis or post-essential thrombocythemia-myelofibrosis

Patient Inclusion Criteria:

  • 18 + years of age,
  • diagnosis of PMF or PPV-MF, either resistant or refractory to, intolerant of, or in the investigator's opinion not candidates for available therapy, must have a life expectancy of at least 6 months

Patient Exclusion Criteria:

  • Subjects with a life expectancy of less than 6 months, subjects in whom MF disease is well controlled with current therapy, females who are pregnant or currently breastfeeding, subjects with inadequate bone marrow, subjects with inadequate liver or renal function, subjects with cardiac disease, subject with currently uncontrolled or unstable angina

Clinical Study Identifier: TX134737

Contact Investigators or Research Sites near you

Start Over

Dr. Tom Davis

Legacy Pharma Research
Bismarck, ND USA
  Connect »